🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Atopic Dermatitis

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children NCT05758532Phase 41 site📍 Geneva Laure Pittet, MD-PhD · Tests: Measles-Mumps-Rubella vaccine (MMR) CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry NCT06238765n/a1 site📍 Waltham CorEvitas Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab NCT07730788n/a1 site📍 Romans-sur-Isère Hôpitaux Drôme Nord Study of Alloknesia in Atopic Dermatitis NCT06923202n/a8 sites📍 Angers📍 Brest📍 La Roche-sur-Yon University Hospital, Brest Mother-Infant Cohort Study in Malaysia and China NCT04919265n/a1 site📍 Kajang Universiti Putra Malaysia · Tests: No intervention - mother-infant cohort study Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete NCT07444008NA1 site📍 Saint Petersburg NovoNatum Ltd · Tests: BioAmicus Complete, Placebo Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population NCT07259343NA1 site📍 Aguascalientes Universidad Autónoma de Aguascalientes · Tests: glycomacropeptide, emollient cream A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis NCT06815380n/a1 site📍 Aarhus Almirall, S.A. · Tests: No Intervention A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema NCT06807268Phase 347 sites📍 Birmingham📍 North Little Rock📍 San Diego Pfizer · Tests: Abrocitinib, Placebo Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031NA1 site📍 Lille University Hospital, Lille · Tests: Biobanking with genetic analysis, SF-12 questionnaire Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland NCT05819463n/a9 sites📍 Basel📍 Bern📍 Buochs Swiss Society of Dermatology and Venereology Molecular Signatures in Inflammatory Skin Disease NCT03358693n/a1 site📍 Kiel Prof. Dr. Stephan Weidinger · Tests: Anti-TNF, Anti-IL12/23, Anti-IL17, Dupilumab, Anti-IL23 PALLAS Laser for Skin Diseases NCT07250997NA1 site📍 Szeged Szeged University · Tests: UVB laser treatment PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry NCT07598058n/a1 site📍 Waltham CorEvitas · Tests: Observational (Non-Interventional) Registry Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment NCT07807228n/a1 site📍 Copenhagen University Hospital Bispebjerg and Frederiksberg Frequency of Palpebral Involvement in Adult With Atopic Dermatitis NCT04826744n/a2 sites📍 Lille📍 Rouen University Hospital, Lille · Tests: Standard dermatology consultation A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis NCT07598383Phase 21 site📍 Hangzhou Jiangsu vcare pharmaceutical technology co., LTD · Tests: VC005 group, VC005 Placebo group ADBest TREAT Registry NCT07904546n/a1 site📍 Hamburg Universitätsklinikum Hamburg-Eppendorf · Tests: Abrocitinib, Baricitinib, Upadacitinib, Dupilumab, Lebrikizumab Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction NCT07183423NA1 site📍 Makati City Makati Medical Center · Tests: Novel barrier repair topical product, Petrolatum Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares NCT07645820n/a13 sites📍 Phoenix📍 Los Angeles📍 Rockville Castle Biosciences Incorporated · Tests: Nevisense electrical impedance spectroscopy ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis NCT06775860Phase 362 sites📍 Hefei📍 Wuhu📍 Beijing Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 Placebo Tablets Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project NCT06300697NA1 site📍 Ann Arbor University of Michigan · Tests: Data and biospecimen collection, Skin biopsies, Oral Food Challenge (OFC) procedures SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center Molecular Signatures of Cutaneous Dupilumab Response NCT05858619Phase 41 site📍 San Francisco University of California, San Francisco · Tests: Dupilumab Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578Phase 12 sites📍 Charlestown📍 Birtinya Seismic Therapeutic AU Pty Ltd · Tests: S-4321 A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis NCT07235384Phase 112 sites📍 Woolloongabba📍 Carlton📍 Beijing Zai Lab (Shanghai) Co., Ltd. · Tests: ZL-1503, Placebo, ZL-1503, Placebo Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis NCT07370909Phase 31 site📍 Beijing Shanghai Longwood Biopharmaceuticals Co., Ltd. · Tests: LW402, Placebo Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults NCT06988605n/a108 sites📍 Birmingham📍 Phoenix📍 Phoenix Galderma R&D Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745Phase 212 sites📍 Brookvale📍 Darlinghurst📍 Kogarah Alphyn Biologics · Tests: zabalafin Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters NCT07056569NA3 sites📍 Milan📍 Verona📍 Voghera Biokosmes Srl · Tests: 047_TD Dermatitis cream twice a day for 28 days
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy